Upacicalcet - EA Pharma/JW Pharmaceutical/Pathalys Pharma/Sanwa Kagaku Kenkyusho/Tasly Pharmaceutical Group
Alternative Names: AJT-240; PLS-240; SK-1403; Upacicalcet sodium hydrate; UPASITALatest Information Update: 23 Aug 2024
At a glance
- Originator Ajinomoto Pharma
- Developer Launch Therapeutics; Pathalys Pharma; Sanwa Kagaku Kenkyusho
- Class Amides; Amines; Antianaemics; Chlorobenzenes; Propionic acids; Small molecules; Sulfonic acids; Toluenes
- Mechanism of Action Calcium-sensing receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Secondary hyperparathyroidism
- Phase III Anaemia
Most Recent Events
- 20 Aug 2024 Pathalys Pharma announces intention to submit NDA to US FDA for hyperparathyroidism in the US
- 15 May 2023 Pathalys Pharma in collaboration with Launch Therapeutics initiates phase-III PATH-2 trial in Secondary hyperparathyroidism in USA (IV) (EudraCT2023-504339-41) (NCT05836220) (PP3003)
- 09 May 2023 Pathalys Pharma plans a phase III trial (PATH-2) for Secondary Hyperparathyroidism (IV) by May 2023 (NCT05836220) (EudraCT2023-504339-41)